[Intravesical instillation in the treatment of superficial tumors of the bladder].
Bladder instillations represent the most significant progress in the management of superficial bladder cancer over the past twenty years. Intravesical chemotherapy significantly alters the rate of recurrence. Intravesical BCG reduces significantly the risk of recurrence and progression. Side effects are common and in the case of BCG severe but rare complications may be encountered during intravesical instillations. Therefore proper use, prevention of complication and careful follow up for tolerance and efficacy of bladder instillations are mandatory. They represent for high risk superficial bladder cancer a therapeutic test. An early failure for these tumors means a potential aggressiveness requiring radical therapy. These various aspects are developed from a practical point of view.
Chopin
D K
DK
Service d'Urologie, Hôpital Henri Mondor, UPRES A CNRS 7054/Université Paris XII, Créteil, France.
D000283:Administration, Intravesical; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D001500:BCG Vaccine / Q000008:administration & dosage* / Q000009:adverse effects; D002277:Carcinoma / Q000188:drug therapy / Q000517:prevention & control / Q000628:therapy; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000517:prevention & control / Q000628:therapy; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D016685:Mitomycin / Q000008:administration & dosage* / Q000009:adverse effects; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D012307:Risk Factors; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000517:prevention & control / Q000628:therapy
D000903:Antibiotics, Antineoplastic; D001500:BCG Vaccine; D016685:Mitomycin
Les instillations endovésicales dans le traitement des tumeurs superficielles de la vessie.